NanoViricides Appoints Project Manager and Engineering Firm for FDA cGMP Plant; Provides Update on anti-Influenza ProgramNanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has retained the services of Mr. Phil Mader and his firm, MPH Engineering, LLC (“MPH”), to help with the overall project management and design engineering of its laboratory and cGMP pilot production facility. This facility will be built by renovating an existing 18,000 sq. ft. light manufacturing plant on a 4.2 acre lot in Shelton, CT, as previously announced. MPH will provide overall engineering and project management services for the whole facility that includes the cGMP facility, laboratories, and office spaces, and will be responsible for overall project management of the detailed design and construction phases. The cGMP area itself will be designed by a separate firm, while MPH will be responsible for successful implementation of the entire project in collaboration with the firm that will provide the cGMP area.
Phil Mader is currently the Director of Engineering at MPH Engineering LLC. Phil has 26 years of mechanical, electrical design and construction leadership experience. His expertise includes design and construction administration of laboratory fit-out projects including the implementation of facility water, air, electrical and process control systems.
Major clients of MPH include well known pharmaceutical companies such as Schering-Plough Corporation and Bristol-Myers Squibb Company.
Both the oral and injectable versions of the Company’s anti-influenza drug have shown extremely high efficacy in animal models against two different influenza A virus strains tested. The Company believes that both candidates will be effective against most, if not all, influenza viruses, including bird flu (H5N1), novel epidemic virus strains, high path influenzas, as well as the seasonal influenza viruses.